vs
Side-by-side financial comparison of BioNTech SE (BNTX) and Cellectis S.A. (CLLS). Click either name above to swap in a different company.
BioNTech SE is the larger business by last-quarter revenue ($1.5B vs $9.5M, roughly 159.8× Cellectis S.A.). BioNTech SE runs the higher net margin — -1.9% vs -265.9%, a 264.0% gap on every dollar of revenue.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
BNTX vs CLLS — Head-to-Head
Income Statement — Q3 2025 vs Q2 2024
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $9.5M |
| Net Profit | $-28.7M | $-25.3M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | -181.1% |
| Net Margin | -1.9% | -265.9% |
| Revenue YoY | — | 375.0% |
| Net Profit YoY | — | -51.9% |
| EPS (diluted) | — | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.5B | — | ||
| Q2 25 | $260.8M | — | ||
| Q1 25 | $182.8M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $128.7M | $9.5M | ||
| Q1 24 | $187.6M | — | ||
| Q3 23 | — | $1.6M | ||
| Q2 23 | — | $2.0M |
| Q3 25 | $-28.7M | — | ||
| Q2 25 | $-386.6M | — | ||
| Q1 25 | $-415.8M | — | ||
| Q3 24 | $198.1M | — | ||
| Q2 24 | — | $-25.3M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $-17.5M | ||
| Q2 23 | — | $-16.6M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 97.3% |
| Q3 25 | -3.1% | — | ||
| Q2 25 | -192.1% | — | ||
| Q1 25 | -292.2% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | -750.7% | -181.1% | ||
| Q1 24 | -270.4% | — | ||
| Q3 23 | — | -1258.1% | ||
| Q2 23 | — | -1180.5% |
| Q3 25 | -1.9% | — | ||
| Q2 25 | -148.2% | — | ||
| Q1 25 | -227.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | — | -265.9% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | -1064.1% | ||
| Q2 23 | — | -831.6% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-0.28 | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $-0.31 | ||
| Q2 23 | — | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $149.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $148.6M |
| Total Assets | — | $407.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $149.0M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $84.4M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $148.6M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $76.1M | ||
| Q2 23 | — | $96.6M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $407.1M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $209.7M | ||
| Q2 23 | — | $227.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $28.9M |
| Free Cash FlowOCF − Capex | — | $27.6M |
| FCF MarginFCF / Revenue | — | 290.5% |
| Capex IntensityCapex / Revenue | — | 13.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $28.9M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.4M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $27.6M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.9M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 290.5% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -2391.4% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 13.2% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 24.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
